BrainsWay Ltd. (BWAY) Stock Analysis
Healthcare · Medical Devices · NasdaqGM
BrainsWay Ltd. (BWAY) posted $52.23M in revenue for fiscal 2025 (up 27.3% year over year), at a 14.6% net margin, and has compounded revenue about 24.3%/yr over five years, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on BrainsWay Ltd.
BrainsWay Ltd. has grown revenue from $27.18M to $52.23M over the last 4 fiscal years, compounding about 24.3% a year. The most recent year was up 27.3%, so growth is actually accelerating.
Net margin sits at 14.6%, up 7.5 points year over year on a 75.4% gross margin.
At today's valuation the market is pricing in roughly 16% annual free-cash-flow growth. It clears 4 of 5 deterministic health checks. The one thing worth a second look in the filings is inventory building faster than sales.
Synthesised from BrainsWay Ltd.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about BrainsWay Ltd.? Check it against the filing
Open the full tool →Paste a headline number you saw about BWAY — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
BrainsWay Ltd. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $27.18M | $31.79M | $41.02M | $52.23M |
| Gross profit | $20.05M | $23.48M | $30.58M | $39.39M |
| Net income | $-13.35M | $-4.20M | $2.92M | $7.63M |
| Net margin | -49.1% | -13.2% | 7.1% | 14.6% |
Source: BrainsWay Ltd. SEC filings (10-K).
BrainsWay Ltd. financial health: 4 of 5 checks passed
- ✓Revenue CAGR over 3 yrs (24.3%/yr)
- ✓Net margin above 10% (14.6%)
- ✓More cash than total debt (cash 69.1M vs debt 0M)
- ✓Free cash flow positive (latest yr) (16.3M)
- ✗Share count falling over 3 yrs (buybacks) (33.1M → 39.2M shares)
Checks computed deterministically from filed annual statements — no AI judgement.
BrainsWay Ltd.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Inventory building faster than salesInventory rose 61.2% versus revenue 27.3% — possible overproduction or softening demand.
- Share count rising (dilution)Shares outstanding grew 18.5% over 3 years (33.1M → 39.2M) — existing holders' stakes are being diluted.
What growth is priced into BWAY stock?
At today's market cap of $598.98M, BrainsWay Ltd. is priced for free-cash-flow growth of about 16% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $16.27M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of BrainsWay Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track BWAY in your portfolio →
BrainsWay Ltd. financial history
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BrainsWay Ltd. — frequently asked questions
What is BrainsWay Ltd.'s revenue?
BrainsWay Ltd. (BWAY) reported revenue of $52.23M for fiscal year 2025, up 27.3% from the prior year, according to its SEC filings.
Is BrainsWay Ltd. profitable?
Yes. BWAY earned net income of $7.63M in fiscal 2025, a net margin of 14.6%.
What is BWAY's P/E ratio?
BrainsWay Ltd. trades at a price-to-earnings ratio of about 67.9 based on the latest data in our nightly-refreshed cache.
How fast is BrainsWay Ltd. growing?
BWAY's revenue grew at roughly 24.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
What is BrainsWay Ltd.'s gross margin?
BWAY's gross margin was 75.4% in fiscal 2025 — gross profit of $39.39M on revenue of $52.23M.
What is BrainsWay Ltd.'s market cap?
BrainsWay Ltd. (BWAY) has a market capitalization of about $598.98M, based on the latest data in our nightly-refreshed cache.
When does BrainsWay Ltd.'s fiscal year end?
BWAY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BWAY stock?
At today's market cap of $598.98M, BrainsWay Ltd. is priced for free-cash-flow growth of about 16% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $16.27M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from BrainsWay Ltd.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.